The current treatment strategy for DKD aims to control blood glucose, blood pressure, and lipid levels by aggressive control, and although there are many Western drugs available for clinical treatment of DKD, only blocking renin-angiotensin-aldosterone system (RAAS) is an effective treatment, and commonly used drugs include angiotensin-converting enzyme inhibitors (ACEis), angiotensin receptor blockers (ARBs), and direct renin inhibitors (DRIs) [4–6], but these drugs are difficult to stop the inflammatory response and renal fibrosis [7]. The gene discussed is REN; the disease is renal fibrosis.